Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Asset Writedowns and Impairment (2022 - 2024)

OptimizeRx's Asset Writedowns and Impairment history spans 3 years, with the latest figure at $77000.0 for Q4 2024.

  • For Q4 2024, Asset Writedowns and Impairment fell 98.77% year-over-year to $77000.0; the TTM value through Sep 2025 reached $77000.0, down 98.8%, while the annual FY2024 figure was $208000.0, 96.91% down from the prior year.
  • Asset Writedowns and Impairment for Q4 2024 was $77000.0 at OptimizeRx, up from -$1000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $6.3 million in Q4 2023 and bottomed at -$1000.0 in Q3 2024.
  • The 3-year median for Asset Writedowns and Impairment is $111000.0 (2023), against an average of $664524.0.
  • The largest annual shift saw Asset Writedowns and Impairment soared 2612.48% in 2023 before it tumbled 100.42% in 2024.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $230785.0 in 2022, then skyrocketed by 2612.48% to $6.3 million in 2023, then crashed by 98.77% to $77000.0 in 2024.
  • Per Business Quant, the three most recent readings for OPRX's Asset Writedowns and Impairment are $77000.0 (Q4 2024), -$1000.0 (Q3 2024), and $132000.0 (Q1 2024).